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.2012.08.0Abstract RNA interference is a post transcriptional gene silencing mechanism that is triggered by
double-stranded RNA (dsRNA). Various attributes of the 30 end structure, including overhang
length and sequence composition, plays a primary role in determining the position of the Dicer
cleavage in both dsRNA and unimolecular, short hairpin RNA (shRNA). The speciﬁcity and
robustness of RNAi have triggered an immense interest in using RNAi as a tool in various settings.
RNAi is a mechanism for controlling normal gene expression which has recently began to be
employed as a potential therapeutic agent for a wide range of disorders, including cancer, infectious
diseases and metabolic disorders. Clinical trials with RNAi have now begin, but major obstacles,
such as off-target effects, toxicity and unsafe delivery methods, have to be overcome before RNAi
can be considered as a conventional drug. It is also used as a tool to improve crops by providing
resistance against parasites and modiﬁed versions of siRNA that are directed against disease caus-
ing genes are being developed, some of which are already tested in clinical trials. In this paper, we
ﬁrst reviewed the RNAi mechanism and then focussed on some of its applications in biomedical
research such as treatment for HIV, viral hepatitis and several other diseases.
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RNA interference (RNAi) is an evolutionary regulatory mech-
anism of most cells that uses 21–25 long siRNA transcripts
to effectively control the expression of desired genes. By inhib-
iting the expression of mRNA transcripts through degrading
or binding sequence speciﬁcally thus hindering translation into
proteins. It is a conserved biological mechanism controlling
normal gene expression. The silencing mechanism occurs at
the levels of transcription, post-transcription and translation.
RNAi can also cause augmentation of gene expression due
to direct effects on the translation (Ebbesen et al., 2008).
Two types of small ribonucleic acid (RNA) molecules –
micro-RNA (miRNA) and small interfering RNA (siRNA) –
are central to RNA interference.Figure 1 Mechanism of RNAi.1.1. DNA-directed RNAi
DNA-directed RNA interference (ddRNAi) uses DNA tem-
plates to synthesize si/shRNA in vivo. ddRNAi depends on
U6 or H1 [RNA polymerase III], or U1 [RNA polymerase
II] promoters for the expression of siRNA target sequences
that have been transfected into mammalian cells (Miyagishi
and Taira, 2002). si/shRNA target sequences can be generated
by PCR, creating ‘‘expression cassettes’’ that can be transfec-
ted directly into cells (Castanotto et al., 2002) or cloned into
expression vectors (Sui et al., 2002).ddRNAi technology in-
volves inserting a DNA construct into a cell, triggering the
production of double stranded RNA (dsRNA), which is then
cleaved into small interfering RNA (siRNA) as part of the
RNAi process, resulting in the destruction of the target mRNA
and knocking-down or silencing the expression of the target
gene. It is not just the size that complicates the cellular uptake
and release of the nucleic acid, but the requirement for gettingthe DNA from the cytoplasm to the nucleus is the major rate-
limiting step differentiating it from synthetic siRNA delivery.
1.2. Mechanism of RNA interference
RNA interference (RNAi) is a phenomenon in which double-
stranded RNA (dsRNA) suppresses the expression of a target
protein by stimulating the speciﬁc degradation of the target
mRNA. Long dsRNA is processed to short interfering RNAs
(siRNAs) by the action of a dsRNA-speciﬁc endonuclease
known as Dicer (Fig. 1) (Bernstein et al., 2001 and Hammond
et al., 2000). The resultant siRNAs usually 21–24 nt in length,
are double stranded, and have 3 overhangs of 2 nt. Exogenous
synthetic siRNAs or endogenously expressed siRNAs can also
be incorporated into the RNA-induced silencing complex
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cessing by Dicer. siRNAs are incorporated into the multi pro-
tein RISC. A helicase in RISC unwinds the duplex siRNA,
which then pairs by means of its unwound antisense strand
to messenger RNAs (mRNAs) that bear a high degree of se-
quence complementarities to the siRNA (Freda, 2004). Cleav-
age of the target mRNA begins at a single site 10 nt upstream
of the 5-most residue of the siRNA-target mRNA duplex
(Elbashir et al., 2001). Although the composition of RISC is
not completely known, it includes members of the Argonaute
family (Angaji et al., 2010) that have been implicated in pro-
cesses directing post transcriptional silencing (Freda, 2004).
Argonaute proteins are essential components of the RNAi
machinery that are associated with distinct classes of small
RNAs to exert their effector functions. Argonaute proteins
are associated with small interfering RNAs (siRNAs) or
microRNAs (miRNAs), and silence gene expression by either
siRNA guided cleavage of the target mRNA transcript, or
by miRNA mediated post transcriptional repression involving
both translational inhibition and/or mRNA degradation.
Functional specialization extends to the biogenesis path-
ways associated with these small RNAs; miRNAs are pro-
cessed from endogenous hairpin precursors by cleavage
events involving the RNAse III enzymes Drosha and Dicer1
(Dcr-1) with its partner loquacious (Loqs). There are two small
RNAs in the RNAi pathway: small interfering RNAs (siR-
NAs) and micro-RNAs (miRNAs) that are generated via pro-
cessing of longer dsRNA and stem loop precursors. Dicer
enzymes play a critical role in the formation of these two effec-
tors of RNAi (Tijsterman et al., 2002). They can cleave long
dsRNAs and stem-loop precursors into siRNAs and miRNAs
in an ATP-dependent manner, respectively.
1.3. Inﬂuence of overhang structure and sequence on Dicer
speciﬁcity and efﬁciency
Dicer processes long double-stranded RNA (dsRNA) and pre-
microRNAs to generate the functional intermediates (short
interfering RNAs and microRNAs) of the RNA interference
pathway. Although overhang composition has no impact on
cleavage product sizes, nucleotide sequence does play a role
in determining Dicer efﬁciency. Overhangs that contain a C
and A in the penultimate and terminal positions (respectively)
are processed most efﬁciently, while those containing an A in
the penultimate position and a U in the terminal position are
less optimal substrates. Overall, ranking the Dicer cleavage
efﬁciency of substrates with different overhangs reveals a hier-
archy with C > U=G>A being the preference at the pen-
ultimate position and A > G=U>C being the order of
terminal nucleotides (Annaleen et al., 2005).
Some studies of substrates with varying 30 overhang lengths
showed that the number of nucleotides in the overhang was a
critical factor in Dicer speciﬁcity. Substrates with overhang
lengths of 1, 2, and 3 nt showed concomitant shifts in the pri-
mary Dicer cleavage position. Increasing the overhang length
further reduced the diversity of cleavage products generating
primarily a 21-nt product. Thus, when the overhang length is
0–3 nt it appears as though Dicer cleaves dsRNA by ‘‘count-
ing’’ a distance of approximately 23 nt from the 30 end of the
overhang to cleave both strands. However, when the overhang
length isP4 nt, the primary cleavage product is similar to thatobserved in duplexes containing 3-nt overhangs. Therefore, in
cases where the overhang length extends beyond 3 nt, Dicer no
longer uses the 30 end of the overhang to determine cleavage
position.
Therefore, RNA end structure, particularly 30 overhang
length, plays a critical role in determining the position and efﬁ-
ciency of Dicer cleavage. (Annaleen et al., 2005) This knowl-
edge has a profound implication for siRNA and shRNA
design. shRNA expression by the Pol III promoter results in
shRNA termini with variable overhang lengths (1–5 Us).
And this variation drastically affects the speciﬁcity of Dicer
cleavage and consequently the functionality of cleaved siRNA.
1.4. Effect of siRNA end structure on silencing efﬁciency
It has recently been suggested that Dicer is involved in siRNA
RISC loading (Lee et al., 2004). In vitro Dicer cleavage assays
demonstrate that end structure inﬂuences Dicer efﬁciency. This
could be due to the fact that siRNA end structure impacts
overall silencing efﬁciency. In general, siRNAs with asymmet-
ric overhangs on the antisense strand (i.e., a 30 overhang on the
antisense strand) performed better than siRNAs with asym-
metric sense strand overhangs. When compared, the difference
in functionality was more profound between structurally asym-
metric siRNA (blunt–overhang, overhang–blunt) than sym-
metric molecules (overhang–overhang, blunt–blunt). This
indicates that the effect on functionality may be the result of
a shift in equilibrium between sense and antisense loading
rather than overall RISC loading efﬁciency (Annaleen et al.,
2005).
2. Designing siRNAs
Small interfering RNAs (siRNAs), the guides that direct RNA
interference (RNAi), provide a powerful tool to reduce the
expression of a single gene in human cells. (Schwarz et al.,
2008) The ability of an siRNA to silence the gene expression
is determined by its sequence and not all target sites are equal
(Peek and Behlke, 2007; Amarzguioui et al., 2006). Other con-
siderations such as cross hybridization and chemical modiﬁca-
tion can also alter the effectiveness of siRNA in addition to the
actual sequence (Peek and Behlke, 2007).
2.1. Location of siRNA
The location of siRNA within the entire gene is less of a con-
cern for potency than the localization of siRNA within a par-
ticular gene exon structure. (Peek and Behlke, 2007) Targets
should be located 50–100 nt downstream of the start codon
(ATG). Therefore, the knowledge of when speciﬁc splice vari-
ants are used is essential to determine how to most effectively
target the desired isoform(s) of the gene.
2.2. Modiﬁcation
siRNAs must have phosphate groups at the 50 end in order to
have activity so it is important not to block the 50 end of the
antisense strand with any modiﬁcations other than the phos-
phate group. (Peek and Behlke, 2007) However, transfected
unmodiﬁed 50OH ends are rapidly phosphorylated by cellular
Table 1 Applications of RNA interference (RNAi) and genes
involved.
Genes Fungi Animals Plants
RdRp QDE1 EGO1 SGS2/SDE1
Elf2c QDE2 RDE1 AGO1
Rnase D – MUT7 –
RNA Helicase – – MUT6
Coiled Coil – – SGS3
Compiled from: http://www.ejb.org accessed on 3.08.2012.
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Regardless of the target sequence, DNA ‘TT’ dinucleotide
overhangs are often added to the 30 ends; however some evi-
dence suggests that using RNA bases may lead to greater po-
tency (Peek and Behlke, 2007).
2.3. Thermodynamic stability
The thermodynamic stability of siRNAs has a signiﬁcant inﬂu-
ence on their potency; thermodynamic asymmetry is funda-
mentally important for siRNA function and strand loading
into RISC. The most effective siRNA has a relatively low
Tm and duplex stability (less stable, more A/U rich) toward
the 50 end of the guide strand and a relatively high Tm (more
stable, more G/C rich) toward the 50 end of passenger strand.
For situations in which selecting thermodynamically favorable
regions is impossible, introducing mismatches (to lower Tm) or
adding modiﬁed bases (to increase Tm) to the siRNA duplex
can create thermodynamic asymmetry. If non-complementary
bases must be introduced, it is important that it is at the 30 end
of the sense strand (passenger strand) rather than the 50 end of
the AS strand (guide strand) to avoid impairing the ability of
the AS strand to anneal to the active target (Peek and Behlke,
2007).
2.4. Sequence characteristics and speciﬁcity
To maintain speciﬁcity, certain sequence characteristics should
be avoided in the guide strand such as homopolymeric runs
(those with four or more identical nucleotides) and nine –base
or greater segments of G/C bases in addition, the secondary
structure of the target and the site accessibility are important
factors in the activity of siRNAs. A moderate to low GC
content (30–52%) tends to be a feature of functional siRNA.
Due to the high speciﬁcity of nucleic acid base pairing, even
a single mismatch in a 19-base sequence can prevent duplex
formation; however, cross hybridization can and does occur.
Therefore, it is very important to screen all candidate siRNAs
for homology to other targets and exclude those with signiﬁ-
cant complementarity.
Like targeted effects, off-target effects (OTEs) are dose
dependent. Therefore, it is important to establish dose re-
sponse proﬁles for all siRNAs in use and always use the lowest
concentration of siRNA that will provide adequate target
knockdown. An additional measure to prevent OTE bias is
to ensure that at least two, and ideally three, independent siR-
NAs against a target give the same result (Peek and Behlke,
2007).
3. Applications of RNA interference in various areas
Besides being an area of intense, upfront basic research, the
RNAi process holds the key to future technological applica-
tions in various sectors, such as in functional genomics, thera-
peutic intervention, agriculture and other areas. Since the
discovery of RNAi, the idea of RNAi therapeutics has blown
into a creative and highly competitive ﬁeld that has attracted
some of the most brilliant minds and it is one of the most
highly invested in ﬁelds in biotechnology research. Some stud-
ies have demonstrated that it is safe to systemically deliver
therapeutically effective doses of siRNAs to primates, leadingthe way for other future systemic applications of RNAi. Some
potential diseases that may be therapeutic targets for RNAi in
the near future include viral diseases, genetic diseases and can-
cer. However, the major obstacles, such as off-target effects,
toxicity and unsafe delivery methods, have to be overcome be-
fore RNAi can be considered as a conventional drug.
3.1. RNAi as a potential therapeutic for humans; genetic
diseases
Dominant negative genetic disorders, in which a mutant allele
of a gene causes disease in the presence of a second, normal
copy, have been challenging since there is no cure and treat-
ments are only to alleviate the symptoms. Current therapies
involving pharmacological and biological drugs are not
suitable to target mutant genes selectively due to structural
indifference of the normal variant of their targets from the
disease-causing mutant ones (Table 1). In instances when the
target contains single nucleotide polymorphism (SNP),
whether it is an enzyme or structural or receptor protein are
not ideal for treatment using conventional drugs due to their
lack of selectivity. Although there is a cooling trend by the
pharmaceutical industry for the potential of RNA interference
(RNAi), RNAi and other RNA targeting drugs (antisense,
ribozyme, etc.) still hold their promise as the only drugs that
provide an opportunity to target genes with SNP mutations
found in dominant negative disorders, genes speciﬁc to patho-
genic tumor cells, and genes that are critical for mediating the
pathology of various other diseases (Seyhan, 2011).
A promising lead toward using RNAi for the treatment of
genetic diseases has been provided by preliminary studies dem-
onstrating how single nucleotide polymorphisms (SNPs) in
mutant allele transcripts can be used as selective targets for
RNAi. Disease causing polyglutamine proteins encoded by
CAG repeat containing transcripts found in several neurolog-
ical diseases present especially challenging targets because
CAG repeats are common to many normal transcripts as well,
and cannot be selectively targeted by siRNAs. Alternatively,
single nucleotide polymorphisms are very often found in mu-
tant allele transcripts, and represent potential selective targets.
Systematic analyses of siRNAs in which the polymorphic
nucleotide is complementary to the mid region of the siRNA
provides an siRNA/SNP combination that is highly selective.
In certain examples, the siRNAs direct selective degradation
of only the mutant transcripts, leaving the wild type transcripts
intact despite having only a single mismatch with the wild type
sequence (Miller et al., 2004a, Miller et al., 2004b). Particular
purine–purine mismatches at positions 10 and 16 relative to 50
end of the guide strand provide selectivity (Schwarz et al.,
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it is important to selectively eliminate the expression of only
the mutant allelic transcript. Many SOD1 mutations are single
nucleotide changes. Since delivery of siRNAs and viral vectors
expressing siRNAs to affected regions of the brain is techni-
cally feasible (McCaffrey et al., 2003), the promise of clinical
use of RNAi for treatment of degenerative, neurological dis-
eases may approach reality soon. Despite the excitement and
promise of therapeutic RNAi, there are many obstacles, the
greatest of which is delivery. Systemically delivered siRNAs
face degradation by nucleases, and the use of viral vectors to
target organs of interest is still in its infancy.
3.2. RNAi in gene regulation and antiviral responses
RNAi and RNAi-related mechanisms play essential roles in the
regulation of cellular gene expression, as well as in innate anti-
viral immune responses. RNAi is regarded as a natural defense
mechanism against mobile endogenous transposons and inva-
sion by exogenous viruses which have dsRNA as an intermedi-
ate product. With this defense mechanism, organisms maintain
genetic integrity and hinder infection (Ebbesen et al., 2008). For
many applications, it may be complicated to introduce short
dsRNAs directly into cells. However, many groups have now
shown that appropriately designed DNA molecules containing
inverted repeat sequences can be transcribed into RNA mole-
cules that form RNA hairpins. If the sequences are chosen cor-
rectly, these are processed by the Dicer nuclease to form
siRNAs. Thus all the methods derived for delivering genes into
cells can in principle be used to deliver siRNAs as well. This
made the application of RNAi therapy for the prevention
and treatment of viral infection convenient (Fig. 2).
RNAi has got a potential for the treatment of viral diseases
such as those caused by the hepatitis C virus (HCV) and the
human immunodeﬁciency virus (HIV). However, there are
important issues and concerns about the therapeutic applica-
tion of this technology, including difﬁculties with delivery
and uncertainty about potential toxicity that needs to be
solved. The HCV genome is a positive-strand RNA molecule
with a single open reading frame encoding a polyprotein that
is processed post-translationally to produce at least ten pro-Figure 2 Antiviral mechaniteins. The only therapy currently available uses combined
interferon (IFN) and ribavirin. Subgenomic and full-length
HCV replicons that replicate and express HCV proteins in sta-
bly transfected human hepatoma cell-derived Huh-7 cells have
been used to study viral replication and the effects of various
antiviral drugs.
Small inhibitory RNAs targeting the internal ribosome en-
try site (IRES) and non-structural protein NS3 and NS5b
encoding mRNAs were shown to inhibit HCV replicon
function in cell culture (Wilson et al., 2003). Furthermore,
anti-HCV siRNAs were shown to ‘‘cure’’ Huh-7.5 cells bearing
persistently replicating HCV replicons. Delivery of the siRNAs
or vectors that carry siRNA expression cassettes is the major
challenge for treatment of HCV. The method of delivery used
in a number of in vivo studies, hydrodynamic intravenous
injection, is not feasible for the treatment of human hepatitis.
Delivery is a problem that must be confronted for any thera-
peutic application of RNAi. A recent report demonstrates that
it is feasible to introduce genetic material into hepatocytes
using catheters or even localized hydrodynamic procedures
(Eastman et al., 2002).
Numerous studies have established the proof of concept that
diseases can be targeted by therapeutic RNAi, and several small
interfering RNAs (siRNAs) are currently being tested in clini-
cal trials (Grimm and Kay, 2007). Despite these rapid ad-
vances, signiﬁcant hurdles still need to be overcome for the
widespread therapeutic application of siRNAs. Perhaps the
greatest challenge is the delivery of effective quantities of siR-
NAs into the cytoplasm of relevant target cells in vivo (Dykxho-
orn and Lieberman, 2006).
HIV was the ﬁrst infectious agent targeted by RNAi per-
haps owing to the fact that the life cycle of HIV is well under-
stood as is its pattern of gene expression. Synthetic and
expressed siRNAs have been used to target a number of early
and late HIV-encoded RNAs including the TAR element, tat,
rev, gag, env, vif, nef (Jacque et al., 2002) and reverse trans-
criptase. Cellular cofactors, such as NFjb, the HIV receptor
CD4 and co-receptors CXCR4 and CCR5 have also been suc-
cessfully down regulated by RNAi resulting in an inhibition of
HIV replication. Moreover, inhibition of HIV replication has
been achieved in numerous human cell lines and primary cellssm of RNA interference.
400 A. Ambesajir et al.including T lymphocytes and hematopoietic stem cell derived
macrophages.
Despite the success of in vitro RNAi-mediated inhibition of
HIV-1, for future clinical applications, targeting the virus di-
rectly represents a substantial challenge since the high viral
mutation rate will certainly lead to escape mutants (Boden
et al., 2003). RNAi-mediated down regulation of cellular co-
factors required for HIV infection is an attractive alternative
or complementary approach.
Delivery of siRNAs or shRNA encoding genetic units to
HIV infected cells is also a challenging problem. The target
cells are primarily T lymphocytes, monocytes and macro-
phages. Since synthetic siRNAs will not persist for long peri-
ods in cells, delivery would have to be done repetitively for
years to effectively treat the infection. Systemic delivery of siR-
NAs to T lymphocytes is a major barrier and probably not fea-
sible. T-cell isolation from patients followed by transduction,
expansion of the transduced cells and re-infusion has been
found to be the preferred path (Dropulic, 2001; Davis et al.,
2004).
There are additional challenges for using siRNAs in the
treatment of HIV-1 infection, including validating the ap-
proach in a relevant animal model and preventing the emer-
gence of variants resistant to treatment because of the high
sequence diversity of the virus. In this issue, Kumar et al.
(2008) exploit a series of recent technical advances to overcome
these obstacles. They demonstrate that targeting a combina-
tion of host and viral proteins with siRNAs can efﬁciently in-
hibit HIV-1 infection in a humanized mouse model. It has been
shown previously that antibodies can be used to deliver siR-
NAs into the cytoplasm of speciﬁc target cells (Song et al.,
2005). This approach decreases the amount of siRNA that is
needed, thereby minimizing the risk of undesired effects in by-
stander cells. In their new work, Kumar et al. use a single-
chain antibody to the CD7 receptor conjugated to a nonamer
arginine peptide (9R) (Fig. 1). The CD7-speciﬁc antibody is
well suited for siRNA delivery because CD7 is expressed by
most T cells and is rapidly internalized. Moreover, this anti-
body has already been used in clinical studies to target toxins
to T cell lymphomas and leukemias. In previous work, Kumar
et al. (2007) demonstrated that the positively charged 9R pep-
tide binds to polyanionic nucleic acids and can be used to de-
liver siRNA to neuronal cells. They now show that these
techniques can be used to suppress HIV-1 replication and pre-
vent CD4+ T cell depletion in vivo in a humanized mouse
model of acquired immune deﬁciency syndrome (AIDS). This
is a signiﬁcant advance, not only because these ﬁndings en-
hance the prospect of a new HIV-1/AIDS therapy but also be-
cause this study introduces an siRNA delivery system that
could be adapted to target different receptors and hence other
cell types. Moreover, given that the binding of the siRNA to
the 9R tag is noncovalent, this approach should make it possi-
ble to easily compare the efﬁcacy of different siRNAs.
3.3. Cancer
The use of RNAi for cancer therapeutics could transform
treatment of this devastating disease. The strong appeal of
RNAi in therapeutics is the potency and speciﬁcity with which
gene expression can be inhibited. What makes RNAi so excit-
ing to many researchers is its potential for knocking out a pro-tein without harming the cell. By comparison, chemotherapy
invariably kills tumors by destroying cancerous cells as well
as healthy cells nearby. The possible targets for various dis-
eases range from oncogenes to growth factors and single nucle-
otide polymorphisms (SNPs).
Animal models are widely used to investigate the therapeu-
tic efﬁciency of RNAi. In vivo utilization of siRNA was effec-
tively performed by targeting the colorectal cancer-associated
gene beta-catenin. Decreased proliferation and diminished
invasiveness were observed following siRNA-mediated silenc-
ing of this gene in human colon cancer cells. Additionally,
when treated cancer cells were placed in a nude mouse, pro-
longed survival was seen compared with mice receiving unma-
nipulated tumors. Similarly, silencing the oncogene H-ras led
to the inhibition of in vivo tumor growth of human ovarian
cancer in a SCID mouse model (Ebbesen et al., 2008). The
challenges for cancer are similar to those faced for other dis-
eases which include ﬁnding good targets, delivery and minimiz-
ing toxicity. Perhaps the most signiﬁcant work utilized
transferin containing nano-particles to target Ewing’s sarcoma
cells in a mouse xenograph model (Boden et al., 2003). This
study demonstrated the feasibility of using non-lipid based
nano-particles for the targeted delivery of siRNAs in a cancer
model, and provides a powerful proof of principle for systemic
delivery of siRNAs to a metastatic cancer.
Interestingly, RNAi may also be exploited to silence path-
ways that facilitate the effects of traditional cancer drugs. This
includes targeting of the multidrug resistance gene (MDR1) for
re-sensitization to chemotherapy and silencing of double-
strand break repair enzymes for enhanced effects of radio-
and chemotherapy (Olivier et al., 2008). Although the trials
are in their early phase, the promises they are showing now
are only indicative of the potential RNAi has for future ther-
apeutic process. There has been progress over the last 4 years
in terms of different delivery system technologies and the
movement of RNAi therapeutics from pre-clinical into human
trials. With the ﬁrst substantial patient data from these RNAi-
based therapies on the near-term horizon, and new studies
likely to begin soon, it is too early to dismiss RNAi therapeu-
tics for cancer treatment.
4. RNAi technology
Developments like the 20-acetoxyethyl (ACE) RNA chemistry
and the incorporation of modiﬁed, especially cationic, nucleo-
tides form the basis for the synthesis of highly stable effective
siRNAs. One of the major problems with synthetic siRNAs is
their low stability in serum. A study was conducted with much
different chemistry at the 20O ribose position such as amino-
ethyl and guanidinoethyl (Odadzic et al., 2008), and it was
shown that siRNA half life and efﬁcacy can be greatly en-
hanced by introducing modiﬁcations at speciﬁc positions both
in the passenger and the guide strand of the siRNA. In this
study off-target effects caused by the incorporation of the pas-
senger strand in RISC were effectively avoided by design of a
nicked passenger strand in the so called small internally seg-
mented interfering RNA (sisiRNA) design. Furthermore, off-
target effects could be avoided by incorporation of speciﬁc
modiﬁcations in the guide strand of the siRNA. Nano-particles
based on chitosan are highly effective for siRNA delivery, par-
ticularly in organs like the lungs.
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nuclear RNA (snRNA) of which the 50 nucleotides 2–11 are
modiﬁed to base-pair with a 10 nucleotide target within the
30 terminal exon of a gene of interest. Binding of the modiﬁed
U1 snRNA inhibits polyadenylation, resulting in degradation
of the transcript and gene knockdown. The U1 snRNA mech-
anism tolerates a single mismatch at positions 1, 2, 9 and 10,
the central 6 nucleotides require perfect base-pairing but do al-
low a single G–U base-pair. The presence of multiple target
sites within the 30 exon enhances inhibition, and a knockdown
of gene expression of up to 700-fold can be achieved.
4.1. Technological applications of RNA interference in Gene
knockdown
The RNA interference pathway is often used to study the func-
tion of genes in cell culture and in vivo in model organisms
(Daneholt, 2007). Double-stranded RNA is synthesized with
a sequence complementary to a gene of interest and introduced
into a cell or organism, where it is recognized as exogenous ge-
netic material and activates the RNAi pathway. Using this
mechanism, researchers can cause a drastic decrease in the
expression of a targeted gene. Studying the effects of this de-
crease can show the physiological role of the gene product.
Since RNAi may not totally abolish expression of the gene,
this technique is sometimes referred as a ‘‘knockdown’’, to dis-
tinguish it from ‘‘knockout’’ procedures in which expression of
a gene is entirely eliminated (Voorhoeve and Agami, 2003).
Extensive efforts in computational biology have been direc-
ted toward the design of successful dsRNA reagents that
maximize gene knockdown but minimize ‘‘off-target’’ effects.
Off-target effects arise when an introduced RNA has a base se-
quence that can pair with and thus reduce the expression of
multiple genes at a time. Such problems are more frequent
when the dsRNA contains repetitive sequences.
Depending on the organism and experimental system, the
exogenous RNA may be a long strand designed to be cleaved
by Dicer, or short RNAs designed to serve as siRNA sub-
strates. In most mammalian cells, shorter RNAs are used be-
cause long double-stranded RNA molecules induce the
mammalian interferon response, a form of innate immunity
that reacts nonspeciﬁcally to foreign genetic material (Naito
et al., 2006). Mouse oocytes and cells from early mouse em-
bryos lack this reaction to exogenous dsRNA and are there-
fore a common model system for studying gene-knockdown
effects in mammals. Specialized laboratory techniques have
also been developed to improve the utility of RNAi in mam-
malian systems by avoiding the direct introduction of siRNA,
for example, by stable transfection with a plasmid encoding
the appropriate sequence from which siRNAs can be tran-
scribed, (Reynolds et al., 2006) or by more elaborate lentiviral
vector systems allowing the inducible activation or deactiva-
tion of transcription, known as conditional RNAi (Stein
et al., 2005).
5. Current trends in clinical trials using RNAi
Since the discovery of RNAi, the idea of RNAi therapeutics
has blown into a creative and highly competitive ﬁeld that
has attracted some of the most brilliant minds and it is one
of the most highly invested in ﬁelds in biotechnology research.Many pharmaceutical companies devoted to RNAi research
are coming up with interesting insights into how human ail-
ments can be cured using the RNAi mechanism. Although
the trials are in their early phase, the promises they are show-
ing now are only indicative of the potential RNAi has for fu-
ture therapeutic process. For example, Nucleonics Inc., a
pharmaceutical company, has initiated a phase l clinical trial
of the systemically administrated RNAi-based therapeutic
NUCB-1000 for the potential treatment of HBV infection.
NUCB-1000 consists of a plasmid DNA construct designed
to produce four different shRNAs, targeting different se-
quences of the HBV genome, under the control of an RNA
polymerase III promoter. The plasmid DNA was formulated
with a proprietary cationic-lipid delivery system. Another anti-
viral strategy that has received much attention is currently un-
der development in a phase l clinical trial for the potential
treatment of HIV. In this approach, CD34+ cells were col-
lected from patients after induction and treated ex vivo. A mix-
ture of shRNA, ribozyme and RNA decoy targeting three
different HIV-related genes: trans-activator of transcription/
regulator of virion (tat/rev), CCR5, and transactivation-
response genes, respectively, were delivered by a lentiviral vec-
tor. The trial combined gene therapy with RNAi, and involved
transfecting CD34+ hematopoietic progenitor cells ex vivo
and then returning the cells to the patients; RNAi treatment
thereby inﬂuences all the CD34+ hematopoietic progenitor
cells’ future progeny, including T-cells. This represents an
important trial since it is the ﬁrst in which a lentivirus was used
as a vector in combination with DNA-directed shRNAs. Pre-
clinical safety and efﬁcacy parameters were encouraging and
the pluripotent precursor cells were able to differentiate nor-
mally after lentiviral transduction (Thu Ngyuen et al., 2008).6. Prospects of utilizing RNAi techniques
Since the onset of its discovery, few breakthroughs in history
can match the level of understanding and research progress
made in RNAi in such a short time. Already, the time when
RNAi research in vitro cell cultures used to attract an awe
stricken attention is long gone as in vivo trials using RNAi
dominate the biotechnology scene.
In a remarkably short time since its discovery in model
organisms, the RNAi pathway has emerged as a powerful tool
for the study of gene function in mammals. The future of
RNAi researches is exciting and there are many applications
to be considered in this ﬁeld. An instance where RNAi technol-
ogy can be used to silence the gene(s) responsible for the pro-
duction of b-oxalylaminoalanine-L-alanine (BOAA), a
neurotoxin found in a leafy vegetable known as Lathyrus sat-
ivus, which is commonly used as a food by the people in the
lower socioeconomic class of the poor nations. Another case
where RNAi may be successfully applied is in the production
of banana varieties resistant to the Banana Bract Mosaic Virus
(BBrMV), currently devastating the banana population in
Southeast Asia and India (Rodoni et al., 1999).
With the use of RNAi in whole animals increasing, a grow-
ing enthusiasm for using RNAi triggers in therapy is antici-
pated. Despite considerable hurdles to overcome it seems
likely that RNAi will ﬁnd a place along side of many conven-
tional approaches in the treatment of diseases, although it is
unclear as how long we have to wait to witness the ﬁrst RNAi
402 A. Ambesajir et al.based drug. The future studies of RNAi will pertain to it for
being investigated for more applications of human, animal
and plant therapeutics. There is great hope that in the near fu-
ture RNAi based treatment for diseases such as Huntington’s
disease, HIV, cancer and other genetic based or infectious dis-
eases will be available.
7. Limitations of RNAi
Despite the proliferation of promising cell culture studies for
RNAi-based drugs, some concern has been raised regarding
the safety of RNA interference, especially the potential for
‘‘off-target’’ effects, in which a gene with a coincidentally sim-
ilar sequence to the targeted gene is also repressed. A computa-
tional genomics study estimated that the error rate of off-target
interactions is about 10%. One major study of liver disease in
mice led to high death rates in the experimental animals, sug-
gested by researchers to be the result of ‘‘oversaturation’’ of
the dsRNA pathway (SrinivasaRao et al., 2011).
8. Conclusion
Clinical trials with RNAi have now begun, but major obsta-
cles, such as off-target effects, toxicity and unsafe delivery
methods, have to be overcome before RNAi can be considered
as a conventional drug. Generally, the success of the therapeu-
tic use of RNAi relies on lack of toxicity, speciﬁcity of silencing
effects and efﬁcacy in vitro and in vivo. So if RNAi is to be used
therapeutically one should weigh the possible harms against
the possible beneﬁts of this method and perform a risk-beneﬁt
analysis. Moreover, as discussed already, delivery methods and
clinical trials are nowhere complete and are under rigorous
developmental programs. With the increase in technological
advancements and novel breakthroughs though it can only
be but anticipated that the future of RNAi therapeutics is
going to be a bright one.Acknowledgement
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